Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$7.01 USD

7.01
39,124

+0.16 (2.34%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $7.01 0.00 (0.00%) 4:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks.com featured highlights include: Kamada, Anhui Conch Cement, Air China and Air Transport Services

by Zacks Equity Research

Zacks.com featured highlights include: Kamada, Anhui Conch Cement, Air China and Air Transport Services

Moumita C. Chattopadhyay headshot

Look Beyond Earnings: 4 Stocks With Increasing Cash Flows

by Moumita C. Chattopadhyay

Cash is an indispensable factor for any company. It gives strength and vitality to a company and is the key to its existence, development and success.

Zacks Equity Research

Zacks.com featured highlights include: Kamada, SunCoke Energy, Great Lakes Dredge & Dock, Herc and SYNNEX

by Zacks Equity Research

Zacks.com featured highlights include: Kamada, SunCoke Energy, Great Lakes Dredge & Dock, Herc and SYNNEX

Zacks Equity Research

Tap These 6 Stocks That Flaunt Impressive Net Profit Margin

by Zacks Equity Research

Let's consider six stocks with a remarkable net profit margin to build a successful portfolio.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for July 16th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Zacks Equity Research

Kamada (KMDA) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Kamada (KMDA) delivered earnings and revenue surprises of 160.00% and 17.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.

Zacks Equity Research

Kamada (KMDA) Stock Moves -1.05%: What You Should Know

by Zacks Equity Research

Kamada (KMDA) closed the most recent trading day at $5.67, moving -1.05% from the previous trading session.

Zacks Equity Research

Kamada (KMDA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Kamada (KMDA) closed the most recent trading day at $5.83, moving +1.57% from the previous trading session.

Zacks Equity Research

Kamada (KMDA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Kamada (KMDA) closed at $6.13 in the latest trading session, marking a +0.02% move from the prior day.

Zacks Equity Research

Is Kamada (KMDA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (KMDA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Kamada to Begin Phase III Study for Inhaled AAT Product in 2H

by Zacks Equity Research

Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.

Moumita Chattopadhyay headshot

5 Stocks With Increasing Cash Flows to Scoop Up Big Gains

by Moumita Chattopadhyay

Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.

Zacks Equity Research

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

by Zacks Equity Research

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

Zacks Equity Research

Acorda to Gain From Inbrija Sales and Neurological Pipeline

by Zacks Equity Research

Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.

Zacks Equity Research

BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M

by Zacks Equity Research

BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

Zacks Equity Research

Kamada (KMDA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Kamada (KMDA) closed at $5.95, marking a -1.16% move from the previous day.

Zacks Equity Research

Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin

by Zacks Equity Research

Here are six stocks with spectacular net profit margins that investors can bank on for stellar returns.

Zacks Equity Research

PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

by Zacks Equity Research

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

Zacks Equity Research

Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth

by Zacks Equity Research

Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.

Zacks Equity Research

Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457

by Zacks Equity Research

Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.

Zacks Equity Research

Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (KMDA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study

by Zacks Equity Research

Puma Biotech (PBYI) increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.

Zacks Equity Research

Kamada (KMDA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Kamada (KMDA) closed at $5.76, marking a +0.17% move from the previous day.

Zacks Equity Research

Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down

by Zacks Equity Research

Puma Biotech (PBYI) out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.